Unknown

Dataset Information

0

Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.


ABSTRACT: Anticancer drug development is inefficient, but genetically engineered murine models (GEMM) and orthotopic, syngeneic transplants (OST) of cancer may offer advantages to in vitro and xenograft systems.We assessed the activity of 16 treatment regimens in a RAS-driven, Ink4a/Arf-deficient melanoma GEMM. In addition, we tested a subset of treatment regimens in three breast cancer models representing distinct breast cancer subtypes: claudin-low (T11 OST), basal-like (C3-TAg GEMM), and luminal B (MMTV-Neu GEMM).Like human RAS-mutant melanoma, the melanoma GEMM was refractory to chemotherapy and single-agent small molecule therapies. Combined treatment with AZD6244 [mitogen-activated protein-extracellular signal-regulated kinase kinase (MEK) inhibitor] and BEZ235 [dual phosphoinositide-3 kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor] was the only treatment regimen to exhibit significant antitumor activity, showed by marked tumor regression and improved survival. Given the surprising activity of the "AZD/BEZ" combination in the melanoma GEMM, we next tested this regimen in the "claudin-low" breast cancer model that shares gene expression features with melanoma. The AZD/BEZ regimen also exhibited significant activity in this model, leading us to testing in even more diverse GEMMs of basal-like and luminal breast cancer. The AZD/BEZ combination was highly active in these distinct breast cancer models, showing equal or greater efficacy compared with any other regimen tested in studies of over 700 tumor-bearing mice. This regimen even exhibited activity in lapatinib-resistant HER2(+) tumors.These results show the use of credentialed murine models for large-scale efficacy testing of diverse anticancer regimens and predict that combinations of PI3K/mTOR and MEK inhibitors will show antitumor activity in a wide range of human malignancies.

SUBMITTER: Roberts PJ 

PROVIDER: S-EPMC3715399 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.

Roberts Patrick J PJ   Usary Jerry E JE   Darr David B DB   Dillon Patrick M PM   Pfefferle Adam D AD   Whittle Martin C MC   Duncan James S JS   Johnson Soren M SM   Combest Austin J AJ   Jin Jian J   Zamboni William C WC   Johnson Gary L GL   Perou Charles M CM   Sharpless Norman E NE  

Clinical cancer research : an official journal of the American Association for Cancer Research 20120807 19


<h4>Purpose</h4>Anticancer drug development is inefficient, but genetically engineered murine models (GEMM) and orthotopic, syngeneic transplants (OST) of cancer may offer advantages to in vitro and xenograft systems.<h4>Experimental design</h4>We assessed the activity of 16 treatment regimens in a RAS-driven, Ink4a/Arf-deficient melanoma GEMM. In addition, we tested a subset of treatment regimens in three breast cancer models representing distinct breast cancer subtypes: claudin-low (T11 OST),  ...[more]

Similar Datasets

2012-08-21 | E-GEOD-35722 | biostudies-arrayexpress
2012-08-21 | GSE35722 | GEO
| 2109499 | ecrin-mdr-crc
| S-EPMC4038579 | biostudies-literature
| S-EPMC7188563 | biostudies-literature